SK Group bets on biotechnology as energy business slows

Korean conglomerate SK Group plans to spend $1 billion to build a biotechnology business, which it hopes will offset slow growth in its existing businesses.

Quick Poll

Which risk do you perceive as being the most significant for EM investors today?

Previous polls ››

September 2016 Magazine
AsianInvestor Magazine

What's in this issue

Expanding ESG in Asia
Q&A: Jupai Holdings
The Brexit fallout for fund managers
Chinese hedge funds step offshore